Gilead Sciences, Inc. (GILD): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de la biotechnologie, Gilead Sciences, Inc. est une force transformatrice, révolutionnant les traitements médicaux à travers son approche innovante du développement pharmaceutique. Avec un modèle commercial stratégique qui plie des recherches de pointe, des solutions thérapeutiques ciblées et un impact mondial sur les soins de santé, Gilead est devenu une puissance pour résoudre les défis médicaux complexes, en particulier dans les traitements antiviraux, la gestion du VIH et l'oncologie. En intégrant de manière transparente l'expertise scientifique avancée, des partenariats stratégiques et une approche centrée sur le patient, la société s'est positionnée à l'avant-garde de l'innovation médicale, offrant constamment des thérapies révolutionnaires qui remontant les limites des soins de santé modernes.

Gilead Sciences, Inc. (GILD) - Modèle commercial: partenariats clés

Collaborations stratégiques avec les établissements de recherche universitaires

En 2024, Gilead Sciences maintient des partenariats de recherche avec:

Institution	Domaine de mise au point	Détails de collaboration
Université de Stanford	Recherche sur le VIH	Financement de la recherche annuelle de 12,5 millions de dollars
Université Johns Hopkins	Recherche d'hépatite	Subvention collaborative de 8,3 millions de dollars

Partenariats de développement pharmaceutique avec les entreprises biotechnologiques

Les principaux partenariats biotechnologiques comprennent:

• Forty Seven, Inc. (acquis en 2020 pour 4,9 milliards de dollars)
• Immunomédicaux (acquis en 2020 pour 21 milliards de dollars)
• Galapagos NV (Contrat de collaboration avec 280 millions d'euros de paiement initial)

Accords de licence avec les fabricants de médicaments mondiaux

Fabricant	Région géographique	Valeur de licence
Mylan Pharmaceuticals	États-Unis	Contrat de licence de 350 millions de dollars
Teva Pharmaceutical	Marchés européens	Affaire de 275 millions de dollars à licence croisée

Coentreprises sur les marchés thérapeutiques émergents

• Chine: coentreprise avec Shanghai Pharmaceuticals
• Inde: partenariat avec les laboratoires du Dr Reddy
• Brésil: accord de collaboration avec Eurofarma Laboratórios

Alliances de recherche avec les réseaux d'essais cliniques

Partenariats actifs du réseau d'essais cliniques:

Réseau	Focus de recherche	Investissement annuel
ACTG (AIDS Clinical Trials Group)	Recherche du VIH / SIDA	22,6 millions de dollars
Groupe de recherche sur le cancer ECOG-ACRIN	Essais en oncologie	18,4 millions de dollars

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: Activités clés

Recherche et développement pharmaceutiques

Dépenses de R&D en 2022: 5,2 milliards de dollars Personnel de recherche: 2 300 employés dédiés à la R&D Brevets totaux détenus: 1 287 brevets pharmaceutiques actifs

Zones de mise au point R&D	Investissement annuel
VIH	1,8 milliard de dollars
Traitements d'hépatite	1,2 milliard de dollars
Recherche en oncologie	850 millions de dollars
Maladies inflammatoires	650 millions de dollars

Découverte de médicaments et gestion des essais cliniques

Essais cliniques actifs en 2022: 87 études en cours Investissement en essai clinique: 1,5 milliard de dollars Taux de réussite des essais cliniques: 14,2%

• Essais de phase I: 32 études actives
• Essais de phase II: 28 études actives
• Essais de phase III: 19 études actives
• Essais de phase IV: 8 études actives

Fabrication et production mondiales de médicaments

Installations de fabrication: 7 sites de production mondiaux Capacité de production annuelle: 2,3 milliards d'unités pharmaceutiques Pays manufacturiers: États-Unis, Irlande, Singapour

Installation de production	Emplacement	Capacité annuelle
Foster City Facility	Californie, États-Unis	680 millions d'unités
Installation de Dublin	Irlande	520 millions d'unités
Fabrication de Singapour	Singapour	420 millions d'unités

Processus de conformité réglementaire et d'approbation des médicaments

Équipe de conformité réglementaire: 450 professionnels Interactions de la FDA en 2022: 62 réunions officielles Souvances réglementaires: 24 nouvelles applications de médicament

Marketing et commercialisation de traitements thérapeutiques

Budget marketing mondial: 1,7 milliard de dollars Représentants commerciaux: 2 800 dans le monde entier Canaux de marketing: la sensibilisation directe des médecins, les plateformes numériques, les conférences médicales

Zone thérapeutique	Dépenses de marketing	Revenus générés
Traitements du VIH	680 millions de dollars	8,2 milliards de dollars
Traitements d'hépatite	450 millions de dollars	5,6 milliards de dollars
Traitements en oncologie	320 millions de dollars	3,9 milliards de dollars

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: Ressources clés

Installations de recherche avancée en biotechnologie

Gilead Sciences maintient des installations de recherche à plusieurs endroits:

• Foster City, Californie (siège social de recherche): 230 000 pieds carrés
• San Dimas, Californie: Installation de recherche en virologie spécialisée
• Investissement total de R&D en 2023: 5,1 milliards de dollars

Lieu de recherche	Taille de l'installation	Focus de recherche primaire
Foster City, CA	230 000 pieds carrés	Recherche pharmaceutique complète
San Dimas, CA	85 000 pieds carrés	Virologie et maladies infectieuses

Portefeuille de propriété intellectuelle

Portfolio de brevets de Gilead à partir de 2023:

• Brevets actifs totaux: 1 287
• Protection de l'expiration des brevets: jusqu'en 2035-2040
• Valeurs clés des brevets du médicament:
  • Biktarvy (VIH): protection des brevets jusqu'en 2035
  • Yescarta (cancer): protection des brevets jusqu'en 2037

Talent scientifique et médical spécialisé

Catégorie des employés	Nombre total	Professionnels de la recherche
Total des employés	14,200	N / A
doctorat Chercheurs	1,600	82% en R&D
Chercheurs MD	340	95% en développement clinique

Capital financier pour la R&D

Ressources financières pour la recherche et le développement:

• 2023 dépenses de R&D: 5,1 milliards de dollars
• Caisse et investissements: 8,3 milliards de dollars
• Attribution annuelle du budget de la R&D: 18-22% des revenus totaux

Infrastructure de test clinique

Métrique d'essai clinique	2023 statistiques
Essais cliniques actifs	87
Sites d'essais cliniques mondiaux	42 pays
Investissement annuel des essais cliniques	1,7 milliard de dollars

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: propositions de valeur

Solutions pharmaceutiques antivirales et spécialisées innovantes

Gilead Sciences a généré 27,3 milliards de dollars de ventes de produits totaux pour l'exercice 2023, avec des zones thérapeutiques clés générant des revenus:

Zone thérapeutique	2023 ventes
Traitements du VIH	13,8 milliards de dollars
Traitements de l'hépatite C	1,5 milliard de dollars
Maladies inflammatoires	2,3 milliards de dollars
Oncologie	1,9 milliard de dollars

Traitements avancés pour le VIH, l'hépatite et l'oncologie

Le portefeuille de produits clés de Gilead comprend:

• Biktarvy (VIH): 11,4 milliards de dollars de ventes annuelles
• Yescarta (oncologie): 673 millions de dollars de ventes annuelles
• Harvoni (hépatite C): 486 millions de dollars de ventes annuelles

Thérapies médicales de haute qualité et validées scientifiquement

Investissement de recherche et développement en 2023: 4,7 milliards de dollars, ce qui représente 17,2% des revenus totaux.

Interventions thérapeutiques ciblées pour les maladies complexes

Catégorie de maladie	Nombre d'essais cliniques en cours
VIH	37 essais actifs
Oncologie	22 essais actifs
Maladies inflammatoires	15 essais actifs

Traitements médicaux révolutionnaires améliorant les résultats des patients

Le pipeline de médicaments propriétaires comprend 27 nouvelles entités moléculaires potentielles dans plusieurs zones thérapeutiques.

• 6 thérapies révolutionnaires potentielles dans le développement clinique à un stade avancé
• 15 nouvelles approches de traitement potentielles en stades précliniques
• La portée mondiale des patients dans 180 pays

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les professionnels de la santé

Gilead maintient la force de vente directe de 1 850 représentants à partir de 2023, ciblant les médecins, les hôpitaux et les cliniques spécialisées dans les maladies infectieuses et les segments d'oncologie.

Segment de clientèle	Fréquence d'engagement	Volume d'interaction annuel
Spécialistes des maladies infectieuses	Trimestriel	12 500 interactions directes
Spécialistes en oncologie	Bimensuel	8 750 interactions directes

Programmes de soutien aux patients et d'assistance

Gilead a investi 127 millions de dollars dans des programmes de soutien aux patients en 2023, couvrant l'accès aux médicaments et l'aide financière.

• Assistance à la copaiement des patients: couverture jusqu'à 7 500 $ par an
• Programmes de médicaments gratuits: servir 15 200 patients avec des ressources financières limitées
• Services de navigation des patients: soutenir 22 500 patients par an

Informations et ressources de santé numérique

Les métriques d'engagement de la plate-forme numérique pour 2023 incluent:

Canal numérique	Utilisateurs actifs mensuels	Taux d'engagement annuel
Portail professionnel de la santé	48,750	72%
Site Web d'information des patients	215,000	65%

Services de consultation médicale personnalisés

Gilead exploite des services de consultation spécialisés avec 325 liaisons en sciences médicales dédiées en 2023.

• Consultations de télémédecine: 17 500 séances annuelles
• Consultations spécialisées sur la gestion des maladies: 9 250 séances annuelles
• Surveillance à distance des patients: soutenir 6 750 patients

Initiatives continues de l'éducation médicale

Gilead a alloué 42,3 millions de dollars aux programmes de formation médicale en 2023.

Type de programme d'éducation	Participants annuels	Investissement du programme
Conférences médicales en ligne	37 500 professionnels de la santé	18,5 millions de dollars
Ateliers de formation clinique	12 750 participants	23,8 millions de dollars

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: canaux

Représentants des ventes pharmaceutiques directes

En 2024, Gilead maintient une force de vente dédiée d'environ 1 850 représentants des ventes pharmaceutiques à travers les États-Unis. Ces représentants ciblent environ 85 000 prestataires de soins de santé spécialisés dans les maladies infectieuses, l'oncologie et la santé du foie.

Catégorie de représentation des ventes	Nombre de représentants	Cibler les spécialités des soins de santé
Équipe de vente de maladies infectieuses	850	Spécialistes du VIH / SIDA
Équipe de vente en oncologie	550	Spécialistes en oncologie
Équipe de vente de maladies du foie	450	Spécialistes de l'hépatologie

Conférences médicales professionnelles de la santé

Gilead participe à environ 120 conférences médicales internationales par an, avec un investissement de 18,5 millions de dollars dédié aux frais de parrainage et d'exposition de la conférence.

• La participation majeure de la conférence comprend une association américaine pour l'étude des maladies hépatiques (AASLD)
• La participation à la conférence atteint environ 42 000 professionnels de la santé chaque année
• Budget de présentation scientifique directe: 7,3 millions de dollars

Plateformes de marketing numérique en ligne

Budget de marketing numérique pour 2024: 22,4 millions de dollars, ciblant les professionnels de la santé par le biais de plateformes de réseautage médical spécialisés.

Plate-forme numérique	Investissement annuel	Public cible
Doxique	5,6 millions de dollars	Médecins
Réseaux professionnels LinkedIn	4,2 millions de dollars	Professionnels de la santé
Sites Web médicaux spécialisés	12,6 millions de dollars	Spécialistes

Réseaux de distributeurs pharmaceutiques

Gilead collabore avec 18 distributeurs pharmaceutiques primaires aux États-Unis, couvrant 92% des établissements de santé.

• Valeur du réseau de distribution pharmaceutique totale: 3,6 milliards de dollars
• Marge de distribution moyenne: 4,7%
• Les distributeurs primaires comprennent Amerisourcebergen, Cardinal Health et McKesson

Journal médical et publicité scientifique

Budget publicitaire de publication scientifique annuelle: 9,7 millions de dollars, ciblant les revues médicales évaluées par des pairs.

Catégorie de publication	Investissement annuel	Portée de circulation
Revues de maladies infectieuses	4,3 millions de dollars	125 000 abonnés
Revues en oncologie	3,2 millions de dollars	95 000 abonnés
Revues d'hépatologie	2,2 millions de dollars	65 000 abonnés

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: segments de clientèle

Hôpitaux et institutions médicales

En 2023, Gilead a servi environ 5 400 hôpitaux et institutions médicales dans le monde. Le volume des achats annuel a atteint 12,3 milliards de dollars en achats pharmaceutiques en milieu hospitalier.

Métriques du segment de l'hôpital	2023 données
Total des hôpitaux servis	5,400
Hôpital pharmaceutique approvisionnement	12,3 milliards de dollars
Taux de pénétration du marché	68.5%

Fournisseurs de soins de santé spécialisés

Gilead soutient 3 200 prestataires de soins de santé spécialisés axés sur les maladies infectieuses, l'oncologie et les traitements hépatiques.

• Spécialistes des maladies infectieuses: 1 450 fournisseurs
• Centres d'oncologie: 890 fournisseurs
• Cliniques d'hépatologie: 860 fournisseurs

Centres de traitement des maladies infectieuses

En 2023, Gilead a collaboré avec 1 100 centres de traitement des maladies infectieuses dédiées dans le monde, avec une valeur de contrat totale de 7,6 milliards de dollars.

Populations de patients immunodéprimés

Gilead dessert environ 620 000 patients immunodéprimés dans plusieurs zones thérapeutiques, avec un segment de traitement du VIH représentant 72% de cette population de patients.

Segment des patients	Patients totaux	Part de marché
Patiens du VIH	446,400	72%
Patients atteints d'hépatite	98,600	16%
Autres patients immunodéprimés	75,000	12%

Systèmes et gouvernements mondiaux

Gilead maintient des contrats avec 142 systèmes nationaux de santé dans 68 pays, avec des marchés publics totaux atteignant 9,4 milliards de dollars en 2023.

• Contrats du gouvernement nord-américain: 4,2 milliards de dollars
• Contrats du gouvernement européen: 3,1 milliards de dollars
• Contrats gouvernementaux Asie-Pacifique: 1,5 milliard de dollars
• Reste des contrats du gouvernement mondial: 600 millions de dollars

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

En 2022, Gilead Sciences a investi 5,1 milliards de dollars dans les frais de recherche et développement, représentant 16,8% du total des ventes de produits. La répartition des dépenses de R&D de l'entreprise comprend:

Zone de focus R&D	Montant d'investissement
Recherche sur le VIH	1,8 milliard de dollars
Maladies inflammatoires / respiratoires	1,2 milliard de dollars
Recherche en oncologie	1,5 milliard de dollars

Investissement et gestion des essais cliniques

Les dépenses des essais cliniques de Gilead en 2022 ont totalisé environ 2,3 milliards de dollars, la distribution suivante:

• Essais de phase I: 420 millions de dollars
• Essais de phase II: 850 millions de dollars
• Essais de phase III: 1,03 milliard de dollars

Coûts de fabrication et de production

Les dépenses de fabrication de Gilead en 2022 étaient de 3,7 milliards de dollars, avec des centres de coûts clés, notamment:

Emplacement de fabrication	Coût de production annuel
États-Unis	2,1 milliards de dollars
Irlande	980 millions de dollars
Autres installations internationales	620 millions de dollars

Compliance réglementaire et dépenses juridiques

Les frais réglementaires et juridiques de Gilead en 2022 s'élevaient à 475 millions de dollars, notamment:

• Conformité de la FDA: 215 millions de dollars
• Litige de brevet: 160 millions de dollars
• Dépenses de dépôt réglementaire: 100 millions de dollars

Infrastructure de marketing et de vente

Les frais de marketing et de vente de Gilead en 2022 ont totalisé 4,2 milliards de dollars, distribués comme suit:

Canal de marketing	Dépense
Force de vente directe	2,1 milliards de dollars
Marketing numérique	680 millions de dollars
Conférence et éducation médicale	420 millions de dollars

Gilead Sciences, Inc. (GILD) - Modèle d'entreprise: Strots de revenus

Ventes de médicaments sur ordonnance

En 2023, Gilead Sciences a déclaré des ventes totales de produits de 27,3 milliards de dollars. Catégories de produits clés incluses:

Catégorie de produits	Revenus de vente (2023)
Médicaments contre le VIH	13,8 milliards de dollars
Traitements de l'hépatite C	3,2 milliards de dollars
Maladies inflammatoires	2,5 milliards de dollars
Traitements en oncologie	1,9 milliard de dollars

Accords de licence pharmaceutique

Gilead a déclaré un revenu de licence de 498 millions de dollars en 2023, avec des partenariats clés, notamment:

• Collaboration Merck pour la recherche sur le VIH et l'hépatite
• AbbVie Partnership for Inflammatory Disease Treatments
• Fourante-sept, Inc. Acquisition pour la recherche en oncologie

Droits de distribution du marché mondial

Répartition des ventes internationales pour 2023:

Région	Revenus de vente	Pourcentage des ventes totales
États-Unis	19,6 milliards de dollars	71.8%
Europe	4,3 milliards de dollars	15.7%
Asie-Pacifique	2,1 milliards de dollars	7.7%
Reste du monde	1,3 milliard de dollars	4.8%

Paiements de redevances à partir de brevets de drogue

Les revenus de redevances pour 2023 ont totalisé 276 millions de dollars, dérivé de:

• Licence de brevet de médicaments contre le VIH
• Traitement de l'hépatite C Propriété intellectuelle
• Redevances antivirales sur les brevets de médicament

Services de recherche et développement contractuels

Revenus collaboratifs de R&D en 2023:

Catégorie de recherche	Revenus collaboratifs
Collaborations de recherche sur le VIH	215 millions de dollars
Partenariats de recherche en oncologie	167 millions de dollars
Recherche sur les maladies inflammatoires	98 millions de dollars

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Value Propositions

You're looking at the core things Gilead Sciences, Inc. offers its customers-the tangible benefits driving their market position as of late 2025. It's about simplifying complex regimens and delivering curative potential where it matters most.

Highly effective, single-tablet HIV regimens for simplified patient adherence

Gilead Sciences, Inc. maintains dominance in the HIV space by offering established, highly effective single-tablet regimens. Biktarvy, for example, remains the number one prescribed regimen in the U.S., holding a 52% market share. This simplifies life for patients immensely. The strength of this portfolio is clear in the financials; total HIV product sales reached $5.3 billion in the third quarter of 2025, a 4% increase year-over-year, even with headwinds like the Medicare Part D redesign expected to impact HIV sales by $900 million in fiscal year 2025. The company has patent protection secured until 2036 for this franchise, which is a huge value anchor.

Here's a snapshot of the key HIV product performance in Q3 2025:

Product	Q3 2025 Sales (Millions USD)	Year-over-Year Growth
Biktarvy	$3,700	6%
Descovy	$701	20%
Total HIV Portfolio	$5,300	4%

First-in-class, twice-yearly injectable HIV prevention option (Yeztugo/lenacapavir)

The introduction of Yeztugo (lenacapavir) as the world's first twice-yearly HIV prevention option is a major value driver, offering a true alternative to daily oral medication. Data from the PURPOSE 2 trial showed this injectable delivered a 96% reduction in HIV infections compared to background HIV incidence. Analysts project this drug's peak sales could reach approximately $4 billion. While the U.S. list price is noted to be more than $28,000, the President's Emergency Plan for AIDS Relief (PEPFAR) has agreed to an initial supply at $64 per person per year for about 1 million people annually, showing a commitment to broad access models.

Targeted Antibody-Drug Conjugate (ADC) therapy, Trodelvy, for solid tumors

Gilead Sciences, Inc. offers Trodelvy, a targeted Antibody-Drug Conjugate (ADC) therapy, providing a critical option in oncology. In the first-line treatment for patients with PD-L1+ metastatic triple-negative breast cancer, Trodelvy combined with Keytruda reduced the risk of disease progression or death by 35% versus the standard of care. Quarterly sales show continued, albeit sometimes volatile, performance; Q3 2025 sales reached $357 million, a 7% increase year-over-year. The drug's Q1 2025 sales were $293 million, which was a 5% decrease, showing the dynamics of inventory and pricing in that segment.

Curative treatments for Hepatitis C (HCV) and chronic care for Hepatitis B (HBV)

The company provides treatments that offer curative potential for Hepatitis C (HCV) and long-term management for Hepatitis B (HBV). The Liver Disease segment demonstrated strong growth, posting $819 million in sales in the third quarter of 2025, which is a 12% increase. This shows the ongoing value delivered in this therapeutic area.

Value in affordability for these chronic conditions is supported through specific programs:

• HCV Co-pay Savings Program: Eligible patients with commercial insurance could pay as little as $5 per month.
• HBV Co-pay Savings Program: Eligible patients with commercial insurance could pay as little as $0 per month.

Patient assistance programs to minimize out-of-pocket costs for eligible U.S. patients

Gilead Sciences, Inc. supports patient access through several programs designed to lower out-of-pocket costs for eligible U.S. patients. The company has committed more than $300 million across 2024 and 2025 to advance U.S. community initiatives. To date, more than 550,000 individuals have received free Gilead medication through its free drug programs for uninsured individuals. For HIV treatment and prevention medications, the Advancing Access Co-pay Savings Program allows eligible patients with commercial insurance to pay as little as $0 per month.

Key support program metrics include:

• Free medication program recipients (cumulative): Over 550,000 individuals.
• U.S. Community Initiative Commitment (2024-2025): More than $300 million.
• Advancing Access HIV Co-pay Minimum: As low as $0 per month.

Finance: draft 13-week cash view by Friday.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Customer Relationships

You're looking at how Gilead Sciences, Inc. maintains its critical connections with the medical community and patients, which is key given its complex, high-value therapies. This isn't just about selling pills; it's about deep, specialized engagement.

High-touch relationships with key opinion leaders and specialist prescribers

Gilead Sciences, Inc. focuses heavily on building relationships with Key Opinion Leaders (KOLs) and specialist prescribers, particularly in its core therapeutic areas. This is essential for driving adoption of novel treatments. For instance, in oncology, the company is positioning itself for the anticipated launch of anito-cel, a potential best-in-class cell therapy for multiple myeloma, expected in 2026.

The company's existing oncology portfolio relies on strong clinical backing. Trodelvy, for example, remains the only approved Trop-2 antibody drug conjugate to show an overall survival benefit in two types of breast cancer, supported by six ongoing Phase 3 trials. By the end of 2024, Gilead's oncology therapies had already reached more than 80,000 people, showing the current reach that high-touch relationships support.

Direct patient support via free drug programs for uninsured individuals

For patients in the U.S. who lack insurance coverage, Gilead maintains direct support through its free drug programs. As of late 2025, the company reported that more than 550,000 individuals have received free Gilead medication through these programs.

This commitment to patient access is backed by financial investment. Gilead committed more than $300 million to advance community initiatives in the U.S. across 2024 and 2025. Note that effective May 5, 2025, Gilead transitioned its free drug programs from a retail pharmacy model to a mail order delivery model.

Co-pay assistance programs to reduce patient financial burden

To help commercially insured patients manage out-of-pocket costs, Gilead deploys several specific Co-pay Savings Programs. These programs are designed to make access immediate, though they exclude patients on government healthcare plans like Medicare or Medicaid.

Here's a quick look at the stated patient cost levels and annual assistance caps for some key programs:

Program/Therapy Area	Minimum Patient Cost (Per Month/Rx)	Maximum Annual Assistance
Advancing Access (HIV/COVID-19)	As little as $0 per month	Not specified (No monthly limit)
Letairis (PAH)	As little as $5 per month	Not specified (No monthly limit)
Zydelig (Oncology)	As little as $5 per prescription	Not specified (No monthly limit)
Support Path (HCV)	As little as $5 per month	Not specified (No monthly limit)
Gilead Oncology (TRODELVY)	As little as $0	Up to $25,000 per calendar year

For the Gilead Oncology Co-pay Program supporting TRODELVY, if an insurer uses a program that adjusts cost-sharing based on the coupon (a co-pay maximizer), Gilead may reduce assistance after providing up to $9,500.

Long-term engagement with global health organizations (PEPFAR, Global Fund)

Gilead Sciences, Inc. has deep, long-term engagement with global health partners to address diseases like HIV in resource-limited settings. A major recent focus is the twice-yearly injectable HIV prevention therapy, lenacapavir.

Key quantitative commitments include:

• Partnering with the Global Fund to supply lenacapavir to reach up to two million people over three years in supported countries, provided at no profit to Gilead.
• A partnership with PEPFAR to further advance access to lenacapavir for PrEP for up to two million people over three years in countries supported by both organizations.
• Signing non-exclusive, royalty-free voluntary licensing agreements with six generic manufacturers to cover 120 high-incidence, resource-limited countries.
• Gilead renewed its agreement with the WHO to donate 304,700 vials of AmBisome® for the period spanning 2023-2025.

The European Medicines Agency validated Gilead's EU-M4all application for lenacapavir for PrEP in February 2025, which helps LLMICs fast-track their own regulatory reviews.

Dedicated medical science liaisons for complex oncology and cell therapies

The relationship with specialists is formalized through dedicated Medical Science Liaisons (MSLs) who serve as scientific resources. These field-based MSLs disseminate clinical information about hematology/oncology products to KOLs, academic institutions, and healthcare professionals.

The MSL role is critical for complex areas like cell therapy, where Gilead's Kite subsidiary is involved. The MSL must possess a strong understanding of the clinical research process and treatment landscape, often requiring an advanced medical/scientific degree. The MSLs are tasked with delivering timely, accurate, and succinct scientific presentations, consistent with promotional compliance and PhRMA guidelines.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Channels

You're looking at how Gilead Sciences, Inc. gets its specialized medicines to patients and payers as of late 2025. It's a mix of high-touch specialty distribution and massive scale through established intermediaries.

Global network of specialty pharmacies and distributors for high-value drugs

Distribution for complex therapies, like Cell Therapy, relies on a highly controlled network. For Kite Pharma's cell therapies, the channel is limited to authorized treatment centers (ATCs). Gilead Sciences reported that Kite therapies are available at over 275 ATCs around the world, with more than 110 of those being leading cancer hospitals in the U.S..

Direct sales force targeting HIV, oncology, and liver disease specialists

The commercial engine for Gilead Sciences' core franchises-HIV, Oncology, and Liver Disease-is driven by a dedicated sales force engaging directly with specialists. The strength of this channel is reflected in the revenue performance:

• HIV portfolio sales reached $5.3 billion in the third quarter of 2025.
• Biktarvy, a key HIV product, generated $3.7 billion in sales in the third quarter of 2025.
• Descovy sales jumped 20% year-over-year to $701 million in the third quarter of 2025.
• Liver Disease portfolio sales were $819 million in the third quarter of 2025, marking a 12% increase from the prior year period.
• Yeztugo, the twice-yearly HIV preventative approved in June 2025, brought in $54 million in sales through the third quarter, with full-year revenue expected around $150 million.

Government procurement channels for global health initiatives (e.g., lenacapavir)

For global public health efforts, Gilead Sciences utilizes direct agreements with large procurement bodies. The access strategy for lenacapavir for HIV prevention involves significant non-profit supply commitments:

Procurement Channel/Agreement	Scope/Target	Financial Term
U.S. State Dept (PEPFAR) & Global Fund	Up to two million people over three years	At no profit to Gilead Sciences until generics meet demand
Voluntary Licensing Partners	120 primarily low- and lower-middle-income countries (LLMICs)	Royalty-free licenses granted in October 2024
Generic Cost Estimate (Example)	Per patient per year (after oral regimen)	Roughly $40

Gilead Sciences aims to complete regulatory submissions for lenacapavir for PrEP in 18 countries, which represent 70% of the HIV burden across the voluntary license region, by the end of 2025.

Internal manufacturing and logistics for Cell Therapy (Kite Pharma)

Kite Pharma maintains a large, in-house manufacturing network to handle personalized cell therapy production. This network is designed for scale and quality control. The global network includes facilities in Southern California, Amsterdam, and Frederick, Maryland. Optimizations across this network were estimated to increase CAR-T manufacturing capacity by 50%. The European hub in the Netherlands, with a €185 million investment, is designed to support manufacture for up to 4,000 patients annually across Europe, the Middle East, and South America. Since 2020, this Dutch facility has manufactured more than 13,000 individual cell therapies.

Wholesalers and major pharmacy benefit managers (PBMs) in the U.S.

The majority of commercial product distribution in the U.S. flows through wholesalers to retail and specialty pharmacies, with PBMs controlling access via formularies. The U.S. PBM market is highly consolidated:

• The top three PBMs-CVS Caremark, Express Scripts, and Optum Rx-collectively process approximately 75% of the market.
• These three companies processed nearly 80% of all equivalent prescription claims in 2024.
• The U.S. PBM market represents a staggering 97% share of the global PBM market.

Gilead Sciences expects total full-year 2025 product sales to be between $28.4 billion and $28.7 billion. The company expects to contribute approximately $2.7 billion in federal and state taxes in 2025.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Customer Segments

You're looking at the core groups that drive the business for Gilead Sciences, Inc. as of late 2025. These segments represent the patients and institutions that rely on their specialized therapies, and the financial scale shows just how significant each one is.

The largest segment remains the patients requiring long-term HIV management and prevention. For the third quarter of 2025, the HIV portfolio generated $5.3 billion in product sales, reflecting a 4% year-over-year growth, which led management to raise the full-year HIV franchise growth expectation to 5%. Within this, the treatment segment is anchored by Biktarvy, which recorded $3.7 billion in sales for Q3 2025. Prevention is a rapidly growing area, with Descovy sales jumping 20% year-over-year to $701 million in Q3 2025, as roughly three quarters of its sales are for HIV prevention (PrEP). The newest prevention agent, Yeztugo, brought in $54 million year to date as of Q3 2025, with a full-year sales expectation around $150 million. The overall PrEP market is expected to grow at 14% to 15% annually.

Oncology patients, especially those with metastatic triple-negative breast cancer (mTNBC), represent a critical, though smaller, revenue stream currently. Trodelvy sales for the third quarter of 2025 were $293 million. Clinical data continues to shape prescribing behavior here; for instance, the ASCENT-03 trial showed Trodelvy reduced the risk of disease progression or death by 38% compared to chemotherapy in a specific first-line mTNBC population. Furthermore, the combination of Trodelvy plus Keytruda showed a 35% risk reduction in PD-L1+ mTNBC in the ASCENT-04 trial.

Patients with chronic liver diseases, specifically those with HBV, HDV, and residual HCV, are served by a portfolio that saw significant growth. The Liver Disease portfolio generated $819 million in sales for Q3 2025, marking a 12% increase year-over-year, largely driven by Livdelzi demand. This growth contrasts with the Q2 2025 figure of $795 million, which was down 4% due to lower HCV sales.

Healthcare providers (HCPs) and hospitals are the direct prescribers and administrators of these complex treatments. Their volume dictates the revenue figures across all therapeutic areas. For context on the overall scale Gilead is managing, total product sales for Q3 2025 were $7.3 billion, while the company generated $4.1 billion in operating cash flow that same quarter.

Government agencies and NGOs focused on global health are essential for access in lower-income settings. Gilead has a plan to supply lenacapavir doses for 2 million people across three years in these regions, equating to 666,000 people annually. In South Africa, a broader rollout is expected to start with 400,000 doses received through a deal with the Global Fund to Fight AIDS. The US cost for this preventative is around $28,000 a year.

Here is a snapshot of the revenue contribution from the core product segments for Q3 2025:

Customer Segment Focus	Product/Area	Q3 2025 Sales Amount	Year-over-Year Change
Patients with HIV (Treatment)	Biktarvy	$3.7 billion	+6%
Patients with HIV (Prevention/PrEP)	Descovy	$701 million	+20%
Patients with HIV (Prevention/PrEP)	Yeztugo (YTD)	$54 million	N/A
Oncology patients (mTNBC/HR+)	Trodelvy	$293 million	-5%
Patients with Liver Diseases (HBV/HDV/PBC)	Liver Disease Portfolio	$819 million	+12%

The needs of these customer segments drive Gilead Sciences, Inc.'s strategic focus, which is reflected in the company's overall financial posture:

• Full-year 2025 product sales guidance range is between $28.4 billion and $28.7 billion.
• As of September 30, 2025, cash, cash equivalents, and marketable debt securities totaled $9.4 billion.
• The company returned $1.0 billion in dividends during Q3 2025.
• The market capitalization stood at $155B as of December 4, 2025.

For the HIV prevention segment, the focus is on expanding reach to populations not currently using PrEP, with researchers presenting strategies for the PURPOSE 5 trial in France and the UK.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Cost Structure

You're looking at the hard numbers that drive Gilead Sciences, Inc.'s operations as of late 2025. The cost structure is heavily weighted toward innovation and getting those innovations to market globally. Here's a breakdown of the key expense areas based on the latest reported figures.

High R&D expenditure, with $1.3 billion spent in Q3 2025

Research and development (R&D) remains a massive cost center, showing the company's commitment to pipeline advancement. For the third quarter of 2025, R&D expenses clocked in at $1.3 billion. This was actually a decrease from the prior year's Q3, primarily due to lower study-related and clinical manufacturing expenses. Year-to-date 2025 R&D expenses were reported at $4.1 billion, which management indicated was in line with 2024 performance for the same period. Management expects full-year 2025 R&D expenses to be roughly flat on a dollar basis compared to 2024.

Significant Selling, General, and Administrative (SG&A) costs for global commercialization

Moving product is expensive, and Gilead Sciences, Inc.'s global footprint requires substantial SG&A spending. In the third quarter of 2025, SG&A expenses were $1.4 billion. This was down 4% compared to the third quarter of 2024, partly due to lower corporate expenses, though this was partially offset by higher HIV promotional expenses. For the twelve months ending September 30, 2025, total SG&A expenses reached $5.886 billion. The expectation for the full year 2025 was a decline in SG&A expenses by a mid to high single-digit percentage compared to 2024's total of $6.091 billion. That's real money spent on sales forces and administrative overhead.

Here's a quick look at how those key operating expenses stacked up for the first three quarters of 2025:

Period	R&D Expenses (GAAP)	SG&A Expenses (GAAP)
Q1 2025	$1.4 billion	$1.3 billion
Q2 2025	$1.5 billion	$1.4 billion
Q3 2025	$1.3 billion	$1.4 billion
Year-to-Date 2025	$4.1 billion	Not explicitly provided as YTD sum

Costs of Revenue, including raw material procurement and complex manufacturing

The cost to actually produce the drugs is managed tightly, reflected in the gross margin figures. Product gross margin for the third quarter of 2025 was 78.6%. On a non-GAAP basis, which strips out certain items, the product gross margin was 86.5% in Q3 2025. This margin performance is what drives the underlying cost of sales, which is a direct reflection of raw material procurement and the complexity of manufacturing these specialized therapies. The non-GAAP product gross margin for the twelve months ending September 30, 2025, was also guided to be around 86.5%.

Acquisition-related expenses and contingent consideration payments

Business development activity creates specific, often non-recurring, costs that hit the income statement. Acquired In-Process Research and Development (IPR&D) expenses in the third quarter of 2025 totaled $170 million. This Q3 figure included a $120 million upfront payment related to the collaboration with Shenzhen Pregene Biopharma Co., Ltd. For the full year 2025, acquired IPR&D was expected to be $900 million. You should note that prior periods included significant, non-repeating charges, such as the $3.9 billion IPR&D expense related to the CymaBay acquisition in Q1 2024. Furthermore, the pending Interius BioTherapeutics acquisition is expected to involve a total cash consideration of $350 million, with related charges anticipated in Q4 2025.

Key acquisition-related costs in 2025 include:

• $170 million Acquired IPR&D in Q3 2025.
• $120 million Upfront payment to Pregene in Q3 2025.
• $61 million Acquired IPR&D in Q2 2025, tied to Kymera partnership.
• Expected full year acquired IPR&D of $900 million.

Capital investment in new U.S. manufacturing and research facilities

Capital expenditures (CAPEX) reflect the investment in the physical assets needed to support future operations. The forecast for Gilead Sciences, Inc.'s CAPEX for the full fiscal year 2025 was set at $568.6 million. This figure represents the planned spending on property, plant, and equipment, which would encompass investments in new or expanded U.S. manufacturing and research facilities, though specific facility spending isn't itemized in the top-line reports. Finance: draft 13-week cash view by Friday.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Revenue Streams

Gilead Sciences, Inc. projects total full-year 2025 product sales to be between $28.4 billion and $28.7 billion.

The dominant HIV franchise remains the cornerstone, delivering $5.3 billion in sales for the third quarter of 2025, representing a 4% increase year-over-year. This growth was driven by both Biktarvy and Descovy performance. The company anticipates its full-year HIV franchise revenue growth to be approximately 5%, despite an expected $900 million headwind from the Medicare Part D redesign in 2025.

The revenue streams from Gilead Sciences, Inc. product sales in the third quarter of 2025 are detailed below:

Product/Franchise Segment	Q3 2025 Revenue (USD)
HIV Product Sales	$5.3 billion
Veklury (remdesivir) Sales	$277 million
Oncology - Cell Therapies Total	$432 million
Oncology - Trodelvy Sales	$357 million
Oncology - Yescarta Sales	$349 million
Oncology - Tecartus Sales	$83 million

The Oncology segment includes the Cell Therapies, which totaled $432 million in Q3 2025 sales, reflecting an 11% decrease compared to the same period in 2024. Trodelvy sales specifically grew 7% to $357 million in the third quarter of 2025. The Cell Therapy sales breakdown includes Yescarta at $349 million and Tecartus at $83 million for the quarter.

Royalty, contract, and other revenues contributed approximately $400 million in the third quarter of 2025, an increase compared to the same period in 2024, primarily due to revenue related to a previous sale of intellectual property not expected to reoccur.

Sales of Veklury (remdesivir) are declining as expected due to lower rates of COVID-19-related hospitalizations, recording $277 million in the third quarter of 2025, a 60% decrease year-over-year. The company continues to expect full-year Veklury revenue of approximately $1 billion.

Further detail on the key drivers within the HIV franchise for Q3 2025 includes:

• Biktarvy sales: $3.7 billion, up 6% year-over-year.
• Descovy sales: $701 million, up 20% year-over-year.
• New HIV prevention product (Yes2Go) sales: $39 million for the third quarter, with $54 million including initial launch weeks in June.